Paul Reider - Jul 22, 2024 Form 4 Insider Report for Coherus BioSciences, Inc. (CHRS)

Role
Chief Commercial Officer
Signature
/s/ Bryan McMichael, as Attorney-in-Fact for Paul Reider
Stock symbol
CHRS
Transactions as of
Jul 22, 2024
Transactions value $
$0
Form type
4
Date filed
7/24/2024, 08:14 PM
Previous filing
Jan 23, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CHRS Stock Option (Right to Buy) Award $0 +40K $0.00 40K Jul 22, 2024 Common Stock 40K $2.41 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On April 11, 2024 the Reporting Person was granted a performance stock option to purchase 200,000 shares of common stock, of which 40,000 of the shares vested and became exercisable on July 22, 2024 in connection with the Closing of the sale of Coherus BioSciences, Inc.'s YUSIMRY franchise.